BR122019026188A2 - - Google Patents

Info

Publication number
BR122019026188A2
BR122019026188A2 BR122019026188A BR122019026188A BR122019026188A2 BR 122019026188 A2 BR122019026188 A2 BR 122019026188A2 BR 122019026188 A BR122019026188 A BR 122019026188A BR 122019026188 A BR122019026188 A BR 122019026188A BR 122019026188 A2 BR122019026188 A2 BR 122019026188A2
Authority
BR
Brazil
Application number
BR122019026188A
Other languages
Portuguese (pt)
Other versions
BR122019026188A8 (pt
BR122019026188B1 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority claimed from BR112015021992-6A external-priority patent/BR112015021992B1/pt
Publication of BR122019026188A2 publication Critical patent/BR122019026188A2/pt
Publication of BR122019026188A8 publication Critical patent/BR122019026188A8/pt
Publication of BR122019026188B1 publication Critical patent/BR122019026188B1/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/978Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/08Hepato-biliairy disorders other than hepatitis
    • G01N2800/085Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR122019026188-1A 2013-03-15 2014-03-10 Métodos para determinar se um indivíduo com esteatose não alcoólica tem esteato-hepatite não alcoólica e para monitorar um indivíduo com esteatose não alcoólica para o desenvolvimento de nash BR122019026188B1 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361787967P 2013-03-15 2013-03-15
US61/787,967 2013-03-15
PCT/US2014/022547 WO2014150198A2 (en) 2013-03-15 2014-03-10 Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
BR112015021992-6A BR112015021992B1 (pt) 2013-03-15 2014-03-10 Método para determinar se um indivíduo tem esteato-hepatite não alcoólica (nash)

Publications (3)

Publication Number Publication Date
BR122019026188A2 true BR122019026188A2 (enrdf_load_html_response) 2017-07-18
BR122019026188A8 BR122019026188A8 (pt) 2022-10-18
BR122019026188B1 BR122019026188B1 (pt) 2024-01-02

Family

ID=50483498

Family Applications (1)

Application Number Title Priority Date Filing Date
BR122019026188-1A BR122019026188B1 (pt) 2013-03-15 2014-03-10 Métodos para determinar se um indivíduo com esteatose não alcoólica tem esteato-hepatite não alcoólica e para monitorar um indivíduo com esteatose não alcoólica para o desenvolvimento de nash

Country Status (9)

Country Link
US (3) US9612248B2 (enrdf_load_html_response)
EP (3) EP2972386B1 (enrdf_load_html_response)
CN (2) CN108957006B (enrdf_load_html_response)
BR (1) BR122019026188B1 (enrdf_load_html_response)
DK (1) DK3296747T3 (enrdf_load_html_response)
ES (3) ES2662108T3 (enrdf_load_html_response)
MX (2) MX360140B (enrdf_load_html_response)
WO (1) WO2014150198A2 (enrdf_load_html_response)
ZA (1) ZA201506441B (enrdf_load_html_response)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104334742A (zh) 2012-01-27 2015-02-04 利兰斯坦福青年大学董事会 解析和定量无细胞rna的方法
EP2972386B1 (en) * 2013-03-15 2018-01-10 Somalogic, Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
EP3267994A4 (en) 2015-03-09 2018-10-31 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
JP2018518169A (ja) * 2015-06-05 2018-07-12 レグルス セラピューティクス インコーポレイテッド 非アルコール性脂肪肝疾患バイオマーカー
EP3414575B1 (en) * 2016-02-08 2024-12-11 SomaLogic Operating Co., Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
WO2017156310A1 (en) * 2016-03-09 2017-09-14 Molecular Stethoscope, Inc. Methods and systems for detecting tissue conditions
CN107630084A (zh) * 2016-07-18 2018-01-26 昆山德诺瑞尔生物科技有限公司 非酒精性脂肪性肝炎的多基因组合检测试剂盒
JP6893406B2 (ja) * 2016-10-19 2021-06-23 日本化薬株式会社 Nashやnafldの進展度の検査方法及び炎症疾患や癌の検査方法
JP7111322B2 (ja) * 2016-12-02 2022-08-02 国立大学法人 東京大学 線維化関連分子に対する抗体およびその医療応用
MX2019011867A (es) 2017-04-03 2020-01-09 Coherus Biosciences Inc Agonista de ppary para el tratamiento de la paralisis supranuclear progresiva.
EP3710831A4 (en) * 2017-11-15 2022-01-12 Beth Israel Deaconess Medical Center, Inc. MARKERS FOR THE DIAGNOSIS AND TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND ADVANCED FIBROSIS OF THE HEPATER
CN111971560B (zh) * 2017-12-01 2024-06-11 康奈尔大学 用于检测和治疗癌症的纳米颗粒和不同的外泌体子集
CA3117488A1 (en) * 2018-10-26 2020-04-30 Molecular Stethoscope, Inc. Disease stratification of liver disease and related methods
MX2021009726A (es) 2019-02-14 2021-09-14 Mirvie Inc Metodos y sistemas para determinar un estado relacionado con el embarazo de un sujeto.
CN110786834B (zh) * 2019-12-09 2022-04-05 中电健康云科技有限公司 一种基于舌象特征和bmi指数的脂肪肝预测模型
CA3166923A1 (en) * 2020-02-10 2021-08-19 Somalogic Operating Co., Inc. Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
CA3196736A1 (en) * 2020-10-30 2022-05-05 Steven K. Grinspoon Kits, reagents and methods for the assessment of liver diseases
WO2022114887A1 (ko) * 2020-11-27 2022-06-02 국립암센터 통합전사체분석 기반 만성 간질환 진단용 복합마커 및 이의 용도
CA3221876A1 (en) * 2021-06-09 2022-12-15 Maxime NACHIT System and method for determining a risk of having or developing steatohepatitis and/or a complication thereof
CN118547066B (zh) * 2024-07-30 2024-11-19 上海交通大学医学院附属仁济医院 一种非酒精性脂肪性肝炎的诊断试剂盒及诊断系统

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
EP0533838B1 (en) 1990-06-11 1997-12-03 NeXstar Pharmaceuticals, Inc. Nucleic acid ligands
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
AU2004251654A1 (en) * 2003-06-02 2005-01-06 Icoria, Inc. Use of genes differentially expressed during aging of liver for treatment and diagnosis
WO2007133586A2 (en) 2006-05-08 2007-11-22 Tethys Bioscience, Inc. Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
WO2008156662A1 (en) 2007-06-14 2008-12-24 George Mason Intellectual Properties, Inc. Methods of diagnosing non-alcoholic steatohepatitis (nash)
EP2172566B2 (en) 2007-07-17 2022-05-18 Somalogic, Inc. Method for generating aptamers with improved off-rates
ES2394152T3 (es) * 2008-07-03 2013-01-22 One Way Liver Genomics, S.L. Huella proteómica para el diagnóstico de la esteatohepatitis no alcohólica (EHNA) y/o esteatosis
US20100124548A1 (en) * 2008-10-29 2010-05-20 University Of Oulu Pharmaceutical product
JP2013509869A (ja) * 2009-11-05 2013-03-21 ノバルティス アーゲー 線維症の進行の予測用バイオマーカー
SG186953A1 (en) 2010-07-09 2013-02-28 Somalogic Inc Lung cancer biomarkers and uses thereof
EP2622104A4 (en) 2010-09-27 2015-04-15 Somalogic Inc BIOMARKERS FOR MESOTHELIOMES AND USES THEREOF
US9103837B2 (en) * 2012-11-07 2015-08-11 Somalogic, Inc. Chronic obstructive pulmonary disease (COPD) biomarkers and uses thereof
EP2972386B1 (en) * 2013-03-15 2018-01-10 Somalogic, Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Also Published As

Publication number Publication date
BR112015021992A8 (pt) 2019-12-03
MX387719B (es) 2025-03-18
BR122019026188A8 (pt) 2022-10-18
CN108957006B (zh) 2021-07-27
CN105143887B (zh) 2018-08-28
MX360140B (es) 2018-10-24
EP3660512C0 (en) 2024-07-24
US20180259537A1 (en) 2018-09-13
WO2014150198A3 (en) 2014-12-18
ZA201506441B (en) 2019-07-31
US9612248B2 (en) 2017-04-04
CN105143887A (zh) 2015-12-09
US9945875B2 (en) 2018-04-17
DK3296747T3 (da) 2020-03-30
US10359435B2 (en) 2019-07-23
CN108957006A (zh) 2018-12-07
WO2014150198A2 (en) 2014-09-25
ES2773999T3 (es) 2020-07-16
ES2662108T3 (es) 2018-04-05
US20170227550A1 (en) 2017-08-10
EP3660512A1 (en) 2020-06-03
ES2986657T3 (es) 2024-11-12
EP2972386A2 (en) 2016-01-20
EP3296747A1 (en) 2018-03-21
EP2972386B1 (en) 2018-01-10
BR112015021992A2 (pt) 2017-07-18
BR122019026188B1 (pt) 2024-01-02
MX2015011756A (es) 2016-01-14
EP3296747B1 (en) 2020-01-08
EP3660512B1 (en) 2024-07-24
HK1220251A1 (en) 2017-04-28
US20140303018A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
AP2016009275A0 (enrdf_load_html_response)
BR112015007533A2 (enrdf_load_html_response)
BR112014018502A2 (enrdf_load_html_response)
BR112014019326A2 (enrdf_load_html_response)
BR112016005676A2 (enrdf_load_html_response)
BR112014018516A2 (enrdf_load_html_response)
BR112014017855A2 (enrdf_load_html_response)
BR112014018480A2 (enrdf_load_html_response)
BR112014020341A2 (enrdf_load_html_response)
BR112014017765A2 (enrdf_load_html_response)
BR112014021878A2 (enrdf_load_html_response)
BR122019026188A2 (enrdf_load_html_response)
BR112016005605A2 (enrdf_load_html_response)
BR112014018468A2 (enrdf_load_html_response)
BR112014017901A2 (enrdf_load_html_response)
BR112014019204A2 (enrdf_load_html_response)
BR112014018207A2 (enrdf_load_html_response)
BR112015015948A2 (enrdf_load_html_response)
BR112014018578A2 (enrdf_load_html_response)
BR112014018483A2 (enrdf_load_html_response)
BR112016014908A2 (enrdf_load_html_response)
BR112015015312A2 (enrdf_load_html_response)
BR112014024039A2 (enrdf_load_html_response)
BR112014018353A2 (enrdf_load_html_response)
BR112014018496A2 (enrdf_load_html_response)

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SOMALOGIC OPERATING CO., INC. (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/03/2014, OBSERVADAS AS CONDICOES LEGAIS